Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | FURIN | P09958 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.35 |
| ▸ | NPY1R | P25929 | 4/20 | 0.35 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094826 | 1.00 | FAP (0.37) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL24335021 | 0.94 | FURIN (0.35) | FAPFURINNPY5RNPY1RNPY4R | |
| SCHEMBL29308956 | 0.92 | NPY5R (0.40) | FAPPTGS1PTGS2NPY5RNPY1R | |
| SCHEMBL2801888 | 0.91 | C3AR1 (0.40) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL22134344 | 0.91 | C3AR1 (0.40) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL13078356 | 0.91 | NPY5R (0.38) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL23420959 | 0.91 | FAP (0.37) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL23256221 | 0.91 | NPY5R (0.38) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL20887736 | 0.91 | FAP (0.37) | FAPPTGS1PTGS2FURINNPY5R | |
| SCHEMBL19257624 | 0.91 | NPY5R (0.38) | FAPPTGS1PTGS2FURINNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |